| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 841 | 2019 |
| Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study S Chawla, R Henshaw, L Seeger, E Choy, JY Blay, S Ferrari, J Kroep, ... The lancet oncology 14 (9), 901-908, 2013 | 636 | 2013 |
| Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ... European journal of cancer 47 (16), 2431-2445, 2011 | 544 | 2011 |
| Basis for effective combination cancer chemotherapy with antimetabolites GJ Peters, CL Van der Wilt, CJA Van Moorsel, JR Kroep, AM Bergman, ... Pharmacology & therapeutics 87 (2-3), 227-253, 2000 | 399 | 2000 |
| Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment EM Dijkgraaf, M Heusinkveld, B Tummers, LTC Vogelpoel, R Goedemans, ... Cancer research 73 (8), 2480-2492, 2013 | 388 | 2013 |
| Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver CL Van Der Wilt, JR Kroep, WJP Loves, MG Rots, CJ Van Groeningen, ... European Journal of Cancer 39 (5), 691-697, 2003 | 310 | 2003 |
| Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis PA Cassier, H Gelderblom, S Stacchiotti, D Thomas, RG Maki, JR Kroep, ... Cancer 118 (6), 1649-1655, 2012 | 297 | 2012 |
| The clinical approach toward giant cell tumor of bone L Van der Heijden, PDS Dijkstra, MAJ van de Sande, JR Kroep, RA Nout, ... The oncologist 19 (5), 550-561, 2014 | 291 | 2014 |
| The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study S de Groot, MPG Vreeswijk, MJP Welters, G Gravesteijn, JJWA Boei, ... BMC cancer 15, 1-9, 2015 | 284 | 2015 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 273 | 2022 |
| Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer S Van de Ven, V Smit, TJA Dekker, JWR Nortier, JR Kroep Cancer treatment reviews 37 (6), 422-430, 2011 | 265 | 2011 |
| Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial S de Groot, RT Lugtenberg, D Cohen, MJP Welters, I Ehsan, ... Nature communications 11 (1), 3083, 2020 | 258 | 2020 |
| Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity JR Kroep, WJP Loves, CL Van Der Wilt, E Alvarez, I Talianidis, E Boven, ... Molecular cancer therapeutics 1 (6), 371-376, 2002 | 256 | 2002 |
| First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an … JR Kroep, M Ouali, H Gelderblom, A Le Cesne, TJA Dekker, ... Annals of oncology 22 (1), 207-214, 2011 | 255 | 2011 |
| Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration V Bossuyt, E Provenzano, WF Symmans, JC Boughey, C Coles, ... Annals of oncology 26 (7), 1280-1291, 2015 | 254 | 2015 |
| Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy EC Rijkmans, RA Nout, I Rutten, M Ketelaars, KJ Neelis, MS Laman, ... Gynecologic oncology 135 (2), 231-238, 2014 | 253 | 2014 |
| Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry SJAM Santegoets, EM Dijkgraaf, A Battaglia, P Beckhove, CM Britten, ... Cancer Immunology, Immunotherapy 64, 1271-1286, 2015 | 220 | 2015 |
| Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses MJ Welters, TC van der Sluis, H van Meir, NM Loof, VJ van Ham, ... Science translational medicine 8 (334), 334ra52-334ra52, 2016 | 217 | 2016 |
| Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05) EJ Blok, JR Kroep, E Meershoek-Klein Kranenbarg, ... JNCI: Journal of the National Cancer Institute 110 (1), 40-48, 2018 | 198 | 2018 |
| A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer EM Dijkgraaf, S Santegoets, AKL Reyners, R Goedemans, MCA Wouters, ... Annals of Oncology 26 (10), 2141-2149, 2015 | 178 | 2015 |
